Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line
Kenji Nakano(National Center for Global Health and Medicine), Shunji Takahashi(Japanese Foundation For Cancer Research), Yuki Funauchi(Japan Association for Development of Community Medicine), Junichi Tomomatsu(The Cancer Institute Hospital), Keiko Hayakawa(Cancer Institute (WIA)), Naoki Fukuda(The Cancer Institute Hospital), Makiko Ono(The Cancer Institute Hospital), Seiichi Matsumoto(Fukuda Denshi (Japan)), Taisuke Tanizawa(Japanese Foundation For Cancer Research), Akihiro Ohmoto(Japanese Foundation For Cancer Research), Xiaofei Wang(Duke University), Keisuke Ae(The Cancer Institute Hospital), Masatoshi Nishizawa(Japanese Foundation For Cancer Research), Tetsuya Urasaki(Japanese Foundation For Cancer Research), Shinichiro Taira(Japanese Foundation For Cancer Research), Yasuyoshi Sato(The Cancer Institute Hospital)
Cited by 9
Related Papers
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264
Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma: An Analysis of 188 Cases
|International Journal of Radiation Oncology*Biology*Physics|2016|182